BioCentury on BioBusiness,
Emerging Company Profile
Tetra using allosteric inhibitors of PDE-4 for depression, cognitive impairment
Related tables, figures and sidebars
Putting a Lid on PDE-4
Monday, September 10, 2012
Efforts to directly inhibit phosphodiesterase-4's active site
to treat neurological indications have failed due to dose-limiting toxicities. Tetra
Discovery Partners LLC is trying to take side effects out of the
equation with allosteric inhibitors of PDE-4 and has preclinical programs in
depression and cognitive impairment.
PDE-4 degrades cyclic AMP
(cAMP), a signaling molecule that activates metabolic pathways in response to
signaling by glucagon. Prior to phosphorylation, the enzyme has about 20%
activity compared with the phosphorylated version.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]